Series 3 (March to July 2021)
|
Date
|
Speaker
|
Title
|
Wednesday 3rd March, 2021
(Business engagement update)
|
Prof Paul Denny
University of Durham, Durham, UK
|
Small molecules to natural products, big pharma to SMEs: antileishmanial work with industry
|
Prof Santuza Teixeira
Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil
|
Development of new vaccines and immunotherapy protocols for leishmaniasis
|
Hosted by Dr Nathaniel Jones
University of York, UK
|
|
Wednesday 24th March, 2021
|
Dr Ashish Arora
Council of Scientific & Industrial Research – (CSIR-CDRI) Lucknow, India
|
Structure of early endosomal Rab5a of Leishmania donovani
|
Hosted by Dr Kalesh Karunakaran
Durham University, UK
|
***NB UK time shifts to BST on 28th March***
|
Wednesday 21st April, 2021
|
Dr Julia Cricco
National University of Rosario (UNR), Rosario, Argentina
|
Heme transport as a target to inhibit Trypanosoma cruzi proliferation: What we learned, and what we don´t yet know
|
Hosted by Dr Nathaniel Jones
University of York, UK
|
Wednesday 5th May, 2021
|
Prof Jeremy Mottram
University of York, UK
|
Protein kinases as drug targets for trypanosomatid parasitic protozoa
|
Hosted by Dr Brian Mantilla
Durham University, UK
|
Wednesday 26th May, 2021
[POSTPONED]
|
Dr Sammer Yousuf
International Centre for Chemical and Biological Sciences (ICCBS), University of Karachi, Pakistan
|
TBC
|
Hosted by Dr Hachemi Kadri
Durham University, UK
|
Wednesday 16th June, 2021
|
Prof Adriano Coelho
University of Campinas (UNICAMP), Brazil
|
Chemotherapy of leishmaniasis in Brazil: studies on susceptibility and resistance in Leishmania
|
Hosted by Dr Katrien van Bocxlaer
University of York, UK
|
Wednesday 7th July, 2021
|
Dr Pegine Walrad
University of York, UK
Hosted by: TBC
|
Pursuing trans-regulators essential to parasites
|
|
